203 related articles for article (PubMed ID: 22091418)
1. Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.
Scholl SM; Kenter G; Kurzeder C; Beuzeboc P
ISRN Oncol; 2011; 2011():403098. PubMed ID: 22091418
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
4. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
6. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma.
Peter M; Stransky N; Couturier J; Hupé P; Barillot E; de Cremoux P; Cottu P; Radvanyi F; Sastre-Garau X
J Pathol; 2010 Jul; 221(3):320-30. PubMed ID: 20527025
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
8. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
Grivas PD; Melas M; Papavassiliou AG
Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
[TBL] [Abstract][Full Text] [Related]
9. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells.
Lee KH; Yim EK; Kim CJ; Namkoong SE; Um SJ; Park JS
Gynecol Oncol; 2005 Jul; 98(1):45-53. PubMed ID: 15907983
[TBL] [Abstract][Full Text] [Related]
12. HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies.
Scholl SM; Kamal M; De Koning L; Kereszt A; Jordanova ES; Ungureanu S; Berns E; Sastre X
Curr Pharm Des; 2013; 19(8):1379-94. PubMed ID: 23016770
[TBL] [Abstract][Full Text] [Related]
13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
14. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
15. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM; Heining C; Agaimy A; Huebschmann D; Bonekamp D; Hutter B; Ehrenberg KR; Fröhlich M; Schlesner M; Scholl C; Schlemmer HP; Wolf S; Mavratzas A; Jung CS; Gröschel S; von Kalle C; Eils R; Brors B; Penzel R; Kriegsmann M; Reuss DE; Schirmacher P; Stenzinger A; Federspil PA; Weichert W; Glimm H; Fröhling S
Ann Oncol; 2017 Jan; 28(1):142-148. PubMed ID: 27687311
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development.
Guleria C; Suri V; Kapoor R; Minz RW; Aggarwal R
Gynecol Oncol; 2019 Oct; 155(1):151-160. PubMed ID: 31375269
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer.
Annunziata C; Buonaguro L; Losito S; Buonaguro FM; Tornesello ML
Infect Agent Cancer; 2013 Jan; 8(1):2. PubMed ID: 23305393
[TBL] [Abstract][Full Text] [Related]
18. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.
Clancy AA; Spaans JN; Weberpals JI
Ann Oncol; 2016 Sep; 27(9):1696-705. PubMed ID: 27329249
[TBL] [Abstract][Full Text] [Related]
19. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
